Beijing Daxiang Biotech Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Beijing Daxiang Biotech Co., Ltd. - overview
Established
2018
Location
Beijing, -, China
Primary Industry
Biotechnology
About
Based in Beijing, China and founded in 2018, Beijing Daxiang Biotech Co. , Ltd. operates as a biochip developer that provides Organ-on-a-Chip and Organoid. In August 2020, the company launched the first batch of domestic commercial organ chips.
In December 2021, Wuhan Biospecimen Bank Co. , Ltd. became the strategic partner of the company. In February 2026, Beijing Daxiang Biotech Co.
, Ltd raised over CNY 100 million in series B funding co-led by new investors Shunxi Fund and E-Town International Industrial Investment. Beijing Daxiang Biotech Co. , Ltd. provides organ chips, organoid for many fields, such as new drug development, disease modeling and individualized precision medicine.
Its products are divided into in vitro models, microarray products, devices and kits. Microarray products include high-throughput barrier function organs-on-chips, organoid expansion chip for dynamic culture and high-throughput 3D microchip for organoid culture and drug screening. The company also provides drug discovery, clinical translation and basic research. The company generates revenue by doing research, development, sales of its products and providing other related services.
The company will use the series B funding to focus on four strategic directions: AI-driven iteration of organoid chip technology, intelligent manufacturing and upgrading of organoid chip life science instruments, construction of intelligent drug screening and precision medicine platforms, and breakthroughs in digital twin and virtual experiment technologies.
Current Investors
Furong Capital, Jiuyo Capital, Shanghai AppTec
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Healthcare IT, Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.daxiangbio.cn
Verticals
HealthTech, Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Beijing Daxiang Biotech Co., Ltd. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & Executive Director & General Manager | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.